CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

regular careWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2866 lanadelumab Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Lanadelumab for Treatment of COVID-19 Disease

So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.

NCT04422509 COVID-19 Biological: lanadelumab Other: regular care

Primary Outcomes

Description: oxygen use in L/min

Measure: oxygen

Time: 2 weeks

Secondary Outcomes

Description: adverse events after lanadelumab administration

Measure: adverse events

Time: 2 weeks

No related HPO nodes (Using clinical trials)